The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Out of specification anti-CD19 CAR T-cell products in aggressive B-cell lymphomas
Prior to tisagenlecleucel (CTL019, tisa-cel) release for commercial use in the United States (US), the final manufactured, patient-specific product must meet specific lot release specifications including total cell viability of at least 80%. Stephen Schuster, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, discusses a prospective, managed access protocol that allows administration of CTL019 to patients with relapsed/refractory (R/R) aggressive B-cell lymphomas who are intended for treatment with US commercial tisa-cel but have “out of specification” (OOS) products, primarily due to low viability. For patients infused with OOS products, overall response rates appear similar to published tisa-cel outcomes for aggressive B-cell non-Hodgkin lymphomas. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
